SPCG-1

Comparison of Estramustine Phosphate to Stilbestrol in the treatment of G3 M Prostatic

Sed posuere consectetur est at lobortis. Donec ullamcorper nulla non metus auctor fringilla. Donec ullamcorper nulla non metus auctor fringilla. Vivamus sagittis lacus vel augue laoreet rutrum faucibus dolor auctor. Nulla vitae elit libero, a pharetra augue. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus.

Fusce dapibus, tellus ac cursus commodo, tortor mauris condimentum nibh, ut fermentum massa justo sit amet risus. Maecenas faucibus mollis interdum. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Maecenas faucibus mollis interdum.

Finished

SPCG-1 info

Principal investigator

Per Olov Hedlund

Contact details

Patients

T1-4,Nx,M1,G2-3 or G3

Treatment

Estramustine 560 mg versus Diethylstilbestrol 3 mg daily

Inclusion period

1984–1989

Number of patients

197

1 publications

Publications of the SPCG-1 trial

Treatment of High-grade, High-stage Prostate Cancer with Estramustine Phosphate or Diethylstilbestrol

Hedlund PO, Jacobsen H, Vaage S, Hahne B, Sandin T, Kontturi M, Nordle Ö, Esposti P and the SPCG-1-Study Group

Scand J Urol Nephrol. 1997

Abstract

Comparison of Estramustine Phosphate to Stilbestrol in the treatment of G3 M Prostatic

SPCG-1 info

Publications of the SPCG-1 trial

Treatment of High-grade, High-stage Prostate Cancer with Estramustine Phosphate or Diethylstilbestrol

More trials

SPCG 19/ Get-Randomized- Prostate (Grand-P): A randomized, multi-center trial of immediate curative therapy compared with standard conservative treatment in older men aged ≥ 75 years with non-metastatic, high-risk prostate cancer

Prostate Cancer Active Surveillance Trigger Trial (PCASTT)

No information available

Primary radical prostatectomy versus primary radiotherapy for locally advanced prostate cancer: an open randomized clinical trial

A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation ± Docetaxel for Non-metastastic Prostate Cancer Patients with a Rising PSA

A Randomized phase III trial of six cycles of docetaxel versus surveillance plus hormonal treatment after radical radiotherapy in patients with intermediate or high-risk prostate cancer (SPCG-13 AdRad)

An open randomised phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in prostate cancer patients with high grade pT3 or margin positive pT2

Randomised trial comparing radical prostatectomy versus radiotherapy plus protocol on follow-up of non-randomised patients with localised prostate cancer

Antiandrogen followed by TAB on biochemical progression versus TAB

An open pilot study evaluating intermittent androgen suppression in patients with advanced prostate cancer

Institution of second-line Estracyt therapy at an increase in PSA values for metastatic prostate cancer

Post-treatment Prostatic Biopsies after Antiandrogen treatment with or without Radiotherapy

Randomized trial of locally advanced prostate cancer. Antiandrogen treatment with or without radiotherapy

A randomized, double-blind, parallel-group trial comparing Casodex 150 mg once daily with placebo in patients with non-metastatic prostate cancer

High-dose Polyestradiol Phosphate versus Total Androgen Blockade

Expectation or radical prostatectomy on early prostate cancer

Cancelled trial due to Socialstyrelsen in Sweden

Orchiectomy plus placebo versus orchiectomy plus cyproteronacetat